Ilyas Sahin, Medical Oncologist at Massachusetts General Hospital, shared on X:
“Biliary tract cancer remains one of the toughest diseases we treat.
Tovecimig (DLL4 x VEGF-A bispecific) receives FDA orphan drug designation.
In pretreated patients, prior data showed improved ORR (17.1% vs 5.3%) and lower PD rates vs paclitaxel. I had the opportunity to contribute as an investigator and author during my time at UF Health Cancer Institute.”
Other articles featuring Ilyas Sahin.
Title: FDA Grants Orphan Drug Designation to Tovecimig for Biliary Tract Cancer
Author: Erin Doran
Read the Full Article.
